收藏切换
Anti-glioblastoma study of YHP-836, a novel PARP1/2 inhibitor, in combination with temozolomide
收藏切换
PDF
Jia-ling DENG, Ting-ting DU, Jie ZHOU, Bai-ling XU, Xiao-guang CHEN, Ming JI*
Acta Pharmaceutica Sinica | 2024, 59(6) : 1656 - 1663
Less
收藏切换
Acta Pharmaceutica Sinica | 2024, 59(6): 1656-1663
Original Articles
Anti-glioblastoma study of YHP-836, a novel PARP1/2 inhibitor, in combination with temozolomide
Full
Jia-ling DENG, Ting-ting DU, Jie ZHOU, Bai-ling XU, Xiao-guang CHEN, Ming JI*
Affiliations
  • State Key Laboratory of Bioactive Substances and Functions of Natural Medicines/Beijing Key Laboratory of Non-clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China
Published: 2024-06-12 doi: 10.16438/j.0513-4870.2023-1455
Outline
收藏切换

The aim of this study was to investigate and evaluate the antitumor effects of a novel poly(ADP-ribose) polymerase (PARP) 1/2 inhibitor, YHP-836, in combination with temozolomide (TMZ) for the treatment of glioblastoma (GBM). The cytotoxicity of YHP-836 was tested alone or in combination with TMZ using MTT assay. Immunoblotting and flow cytometry were also employed to assess the combination activity of YHP-836 and TMZ in multiply GBM cell lines. Further, the antitumor activity of YHP-836 and TMZ was evaluated using subcutaneous and orthotopic mice xenograft tumor models. All procedures were approved by the Ethics Committee for Animal Experiments of the Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College and conducted under the Guidelines for Animal Experiments of Peking Union Medical College. The approval number is 00009138. It was demonstrated that the combination of YHP-836 and TMZ increased the cytotoxicity against GBM cells and upregulated histone H2AX phosphorylation (γH2AX) expression levels compared to TMZ treatment alone. The combination also led to the S-phase cell cycle arrest. Moreover, YHP-836 significantly enhanced TMZ antitumor effects without significantly increasing chemotherapy drug toxicity in vivo, whereas YHP-836 alone showed limited therapeutic efficacy against GBM. In conclusion, the novel PARP1/2 inhibitor, YHP-836, sensitizes TMZ and provides a basis for further investigation into its mechanism of action. These findings suggest that YHP-836 may be a potential candidate for combination therapy with TMZ in patients with TMZ resistance.

temozolomide  /  PARP inhibitor  /  glioblastoma  /  poly(ADP-ribose) polymerase  /  drug combination
Jia-ling DENG, Ting-ting DU, Jie ZHOU, Bai-ling XU, Xiao-guang CHEN, Ming JI. Anti-glioblastoma study of YHP-836, a novel PARP1/2 inhibitor, in combination with temozolomide[J]. Acta Pharmaceutica Sinica, 2024 , 59 (6) : 1656 -1663 . DOI: 10.16438/j.0513-4870.2023-1455
Year 2024 volume 59 Issue 6
PDF
217
87
Cite this Article
BibTeX
Article Info
doi: 10.16438/j.0513-4870.2023-1455
  • Receive Date:2023-12-28
  • Online Date:2025-11-26
  • Published:2024-06-12
Article Data
Affiliations
History
  • Received:2023-12-28
  • Revised:2024-02-02
Funding
Affiliations
    State Key Laboratory of Bioactive Substances and Functions of Natural Medicines/Beijing Key Laboratory of Non-clinical Drug Metabolism and PK/PD Study, Institute of Materia Medica, Chinese Academy of Medical Sciences, Beijing 100050, China
References
Share
https://castjournals.cast.org.cn/joweb/yxxb/EN/10.16438/j.0513-4870.2023-1455
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数

Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)

Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT